Behavioral and Pharmacological Treatment for Insomnia
Primary Purpose
Sleep Initiation and Maintenance Disorders
Status
Completed
Phase
Phase 4
Locations
Canada
Study Type
Interventional
Intervention
Cognitive-behavior therapy
zolpidem
Sponsored by
About this trial
This is an interventional treatment trial for Sleep Initiation and Maintenance Disorders focused on measuring Insomnia, Sleep Disorders, Sleep Deprivation
Eligibility Criteria
Inclusion criteria: Subjective complaint of difficulties initiating or maintaining sleep, accompanied by marked distress or daytime impairments due to insomnia Sleep difficulties present 3 nights or more per week and lasting for more than 6 months Exclusion criteria: Major medical or psychiatric problems
Sites / Locations
- Laval University
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00042146
First Posted
July 24, 2002
Last Updated
May 17, 2013
Sponsor
Laval University
Collaborators
National Institute of Mental Health (NIMH)
1. Study Identification
Unique Protocol Identification Number
NCT00042146
Brief Title
Behavioral and Pharmacological Treatment for Insomnia
Official Title
Behavioral and Pharmacological Treatment for Insomnia
Study Type
Interventional
2. Study Status
Record Verification Date
May 2013
Overall Recruitment Status
Completed
Study Start Date
December 2001 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Laval University
Collaborators
National Institute of Mental Health (NIMH)
4. Oversight
5. Study Description
Brief Summary
This study will evaluate the long- and short-term effects of cognitive-behavior therapy (CBT), alone and in combination with zolpidem (Ambien®), for chronic insomnia.
Detailed Description
Insomnia is a prevalent health concern which is often associated with functional impairments, reduced quality of life, and increased health-care costs. The proposed study may provide useful information about optimal models for integrating behavioral and pharmacological therapies for the clinical management of insomnia.
Participants are randomly assigned to CBT or CBT plus medication. After the 6-week acute treatment phase, participants enter into a 6-month extended treatment phase. Of those treated with CBT alone initially, responders are randomized to extended CBT or no treatment. Of those receiving the combined CBT plus medication approach initially, responders are randomized to an extended treatment consisting of either CBT plus medication (used on an as needed schedule) or CBT alone (plus medication tapering). Outcome is evaluated across measures of sleep, clinical ratings, and several indices of daytime functioning. The measures are administered at baseline, at the end of the acute and extended treatment phases, and at 6, 12, and 24-month follow-up.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Initiation and Maintenance Disorders
Keywords
Insomnia, Sleep Disorders, Sleep Deprivation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
160 (false)
8. Arms, Groups, and Interventions
Intervention Type
Behavioral
Intervention Name(s)
Cognitive-behavior therapy
Intervention Type
Drug
Intervention Name(s)
zolpidem
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria:
Subjective complaint of difficulties initiating or maintaining sleep, accompanied by marked distress or daytime impairments due to insomnia
Sleep difficulties present 3 nights or more per week and lasting for more than 6 months
Exclusion criteria:
Major medical or psychiatric problems
Facility Information:
Facility Name
Laval University
City
Quebec City
State/Province
Quebec
ZIP/Postal Code
G1K 7P4
Country
Canada
12. IPD Sharing Statement
Citations:
PubMed Identifier
30871960
Citation
Rochefort A, Jarrin DC, Belanger L, Ivers H, Morin CM. Insomnia treatment response as a function of objectively measured sleep duration. Sleep Med. 2019 Apr;56:135-144. doi: 10.1016/j.sleep.2019.01.016. Epub 2019 Jan 31.
Results Reference
derived
PubMed Identifier
28364426
Citation
Beaulieu-Bonneau S, Ivers H, Guay B, Morin CM. Long-Term Maintenance of Therapeutic Gains Associated With Cognitive-Behavioral Therapy for Insomnia Delivered Alone or Combined With Zolpidem. Sleep. 2017 Mar 1;40(3):zsx002. doi: 10.1093/sleep/zsx002.
Results Reference
derived
PubMed Identifier
27658218
Citation
Morin CM, Beaulieu-Bonneau S, Belanger L, Ivers H, Sanchez Ortuno M, Vallieres A, Savard J, Guay B, Merette C. Cognitive-behavior therapy singly and combined with medication for persistent insomnia: Impact on psychological and daytime functioning. Behav Res Ther. 2016 Dec;87:109-116. doi: 10.1016/j.brat.2016.09.002. Epub 2016 Sep 13.
Results Reference
derived
PubMed Identifier
19454639
Citation
Morin CM, Vallieres A, Guay B, Ivers H, Savard J, Merette C, Bastien C, Baillargeon L. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA. 2009 May 20;301(19):2005-15. doi: 10.1001/jama.2009.682.
Results Reference
derived
Learn more about this trial
Behavioral and Pharmacological Treatment for Insomnia
We'll reach out to this number within 24 hrs